IL97019A - Pharmaceutical compositions containing erythropoietin and cyclodextrin - Google Patents

Pharmaceutical compositions containing erythropoietin and cyclodextrin

Info

Publication number
IL97019A
IL97019A IL97019A IL9701991A IL97019A IL 97019 A IL97019 A IL 97019A IL 97019 A IL97019 A IL 97019A IL 9701991 A IL9701991 A IL 9701991A IL 97019 A IL97019 A IL 97019A
Authority
IL
Israel
Prior art keywords
cyclodextrin
pharmaceutical compositions
compositions containing
radical
alk
Prior art date
Application number
IL97019A
Other languages
English (en)
Other versions
IL97019A0 (en
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10670074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL97019(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL97019A0 publication Critical patent/IL97019A0/xx
Publication of IL97019A publication Critical patent/IL97019A/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Perforating, Stamping-Out Or Severing By Means Other Than Cutting (AREA)
  • Processing Of Stones Or Stones Resemblance Materials (AREA)
  • Re-Forming, After-Treatment, Cutting And Transporting Of Glass Products (AREA)
  • Manufacturing Of Magnetic Record Carriers (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
IL97019A 1990-01-29 1991-01-24 Pharmaceutical compositions containing erythropoietin and cyclodextrin IL97019A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909001987A GB9001987D0 (en) 1990-01-29 1990-01-29 Improved cyclodextrin based erythropietin formulation

Publications (2)

Publication Number Publication Date
IL97019A0 IL97019A0 (en) 1992-03-29
IL97019A true IL97019A (en) 1997-07-13

Family

ID=10670074

Family Applications (1)

Application Number Title Priority Date Filing Date
IL97019A IL97019A (en) 1990-01-29 1991-01-24 Pharmaceutical compositions containing erythropoietin and cyclodextrin

Country Status (20)

Country Link
US (1) US5376632A (de)
EP (1) EP0513072B1 (de)
JP (1) JP2997052B2 (de)
KR (1) KR0183445B1 (de)
AT (1) ATE107518T1 (de)
AU (1) AU648061B2 (de)
CA (1) CA2074820C (de)
DE (1) DE69102627T2 (de)
DK (1) DK0513072T3 (de)
ES (1) ES2059115T3 (de)
FI (1) FI105012B (de)
GB (1) GB9001987D0 (de)
HU (1) HU218213B (de)
IE (1) IE65209B1 (de)
IL (1) IL97019A (de)
NO (1) NO304728B1 (de)
NZ (1) NZ236938A (de)
PT (1) PT96593B (de)
WO (1) WO1991011200A1 (de)
ZA (1) ZA91620B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
IL116085A (en) 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
WO1997039761A1 (en) 1996-04-19 1997-10-30 Alpha Therapeutic Corporation A process for viral inactivation of lyophilized blood proteins
US5754937A (en) 1996-05-15 1998-05-19 Stackpole Limited Hi-density forming process
SI0977582T1 (en) * 1997-03-18 2002-12-31 Roche Diagnostics Gmbh Pharmaceutical combined preparations containing erythropoietin and iron preparations
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
CA2342797A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US6696056B1 (en) * 1999-04-09 2004-02-24 Ortho Mcneil Pharmaceutical, Inc. Pharmaceutical compositions of erythropoietin
AU2001276737A1 (en) * 2000-08-04 2002-02-18 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
US20060235366A1 (en) * 2000-12-20 2006-10-19 Fox Hollow Technologies, Inc. Method of evaluating a treatment for vascular disease
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
KR20040018434A (ko) * 2001-07-09 2004-03-03 야마노우치세이야쿠 가부시키가이샤 서방성 주사제용 조성물 및 이의 제조방법
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
CA2528988C (en) 2003-06-10 2012-05-01 Lg Life Sciences Ltd. Stable, aqueous solution of human erythropoietin, not containing serum albumin
EP1537876A1 (de) * 2003-12-01 2005-06-08 BioGeneriX AG Formulierung einer Erythropoietin Lösung
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20110236902A1 (en) * 2004-12-13 2011-09-29 Tyco Healthcare Group Lp Testing a patient population having a cardiovascular condition for drug efficacy
US7794413B2 (en) * 2005-04-19 2010-09-14 Ev3, Inc. Libraries and data structures of materials removed by debulking catheters
CU23317A1 (es) * 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
EA200900571A1 (ru) 2006-10-20 2009-12-30 Айкос Корпорейшн Композиции chk1 ингибиторов
ES2632164T3 (es) * 2010-07-06 2017-09-11 Augustinus Bader Aplicación tópica de eritropoyetina para uso en el tratamiento de lesiones de la córnea
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
US11583584B1 (en) * 2015-10-28 2023-02-21 Coherus Biosciences, Inc. Stable protein compositions and methods of their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4920214A (en) * 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
PT88490B (pt) * 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers

Also Published As

Publication number Publication date
ES2059115T3 (es) 1994-11-01
FI923402A (fi) 1992-07-28
HU218213B (hu) 2000-06-28
HUT62198A (en) 1993-04-28
NO922990L (no) 1992-07-29
EP0513072A1 (de) 1992-11-19
DE69102627T2 (de) 1994-11-03
JP2997052B2 (ja) 2000-01-11
NO922990D0 (no) 1992-07-29
FI923402A0 (fi) 1992-07-28
PT96593B (pt) 2001-06-29
JPH05503700A (ja) 1993-06-17
DE69102627D1 (de) 1994-07-28
DK0513072T3 (da) 1994-08-01
GB9001987D0 (en) 1990-03-28
IL97019A0 (en) 1992-03-29
AU7149791A (en) 1991-08-21
KR0183445B1 (en) 1999-05-01
ATE107518T1 (de) 1994-07-15
CA2074820C (en) 2003-10-14
CA2074820A1 (en) 1991-07-30
NO304728B1 (no) 1999-02-08
AU648061B2 (en) 1994-04-14
HU9202432D0 (en) 1992-10-28
PT96593A (pt) 1991-10-15
IE65209B1 (en) 1995-10-04
IE910286A1 (en) 1991-07-31
ZA91620B (en) 1992-10-28
US5376632A (en) 1994-12-27
EP0513072B1 (de) 1994-06-22
NZ236938A (en) 1992-07-28
FI105012B (fi) 2000-05-31
WO1991011200A1 (en) 1991-08-08

Similar Documents

Publication Publication Date Title
IL97019A (en) Pharmaceutical compositions containing erythropoietin and cyclodextrin
TW374768B (en) 8-naphthalimide derivative and processes for their manufacture
TW334418B (en) Stilbene derivatives and pharmaceutical compositions
MX9803761A (es) Nuevos agentes de transfeccion y sus aplicaciones farmaceuticas.
IL118047A0 (en) Sulfated oligosaccharides pharmaceutical compositions containing them and their use
MY116624A (en) Polymer-bound camptothecin derivatives.
MY111556A (en) Substituted azadioxacycloalkenes.
GR3034924T3 (en) Novel peptide derivatives
ATE36859T1 (de) 4'-demethyl-4-epipodophyllotoxin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
IL94433A0 (en) Aminophenol derivatives,their preparation and pharmaceutical compositions containing them
ZA855770B (en) Detergent compositions
ATE207516T1 (de) Wasserbeständige metallpigmente enthaltende paste und herstellungsverfahren davon
EP0479465A3 (de) Verhütung von Kesselstein
BG100661A (en) Aryl acetic acid derivatives
MD1560G2 (ro) Compuşi ciclici, compoziţii farmaceutice pe baza lor şi metode de tratament al infecţiilor sau bolilor provocate de retrovirusuri
MY120683A (en) New phenylamidine derivatives, processes for their preparation and their use as pharmaceuticals.
EP0450420A3 (en) Dihydropyridines substituted by heterocycles, process for their preparation and their use in medicaments
MY132057A (en) Quinoxalinones, a process for their preparation and their use
ATE166647T1 (de) Bis-naphthalimide für die behandlung von krebs
ES8604988A1 (es) Procedimiento para preparar nuevos esteroides sustituidos en posicion 10.
ES8604604A1 (es) Un procedimiento para la produccion de 3,3",4"-tri-o-acilespiramicina i"-.
IL108856A0 (en) Hydroxymethyl-furazancarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
BG61811B1 (en) Preparation for plant disease control
MX9206116A (es) Productos de reaccion de aminadiol y de substancia polifuncional y su aplicacion en las composiciones de pinturas cationicas electrodepositables
NZ510116A (en) Tricyclic delta-3-piperidines as pharmaceuticals

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed